U
ANIP icon

UBS’s ANI Pharmaceuticals ANIP Stock Holding History

UBS’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-600
Closed -$4K – 10323
2013
Q2 		$4K Buy
+600
New +$4.2K ﹤0.01% 9381

Other funds holding ANIP

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
FIM
Foresters Investment Management New York $5.05B AUM 5.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

UBS's ANIP Position: Q3 2014 in Review

UBS increased its ANI Pharmaceuticals (ANIP) stake by 312% in Q3 2014, buying an estimated $57.6K and bringing the position to 2,540 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #6385.

UBS first reported a position in ANIP in Q2 2013 and has held it in 6 quarters since. The position peaked at $482K in Q1 2014. 72 funds tracked by Wall St. Rank hold ANIP as of Q3 2014.

  • UBS held 2,540 shares of ANI Pharmaceuticals worth $72K as of Q3 2014.
  • UBS bought 1,923 ANI Pharmaceuticals shares in Q3 2014, an estimated $57.6K.
  • ANI Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6385 holding.
  • UBS first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's ANI Pharmaceuticals position peaked at $482K in Q1 2014.
  • 72 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.